Related Experiment Video
Updated: Oct 9, 2025

Quantification and Whole Genome Characterization of SARS-CoV-2 RNA in Wastewater and Air Samples
Published on: June 30, 2023
Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020
Shelly Bolotin1,2,3, Vanessa Tran1,3, Shelley L Deeks1,2
1Public Health Ontario, Toronto, Ontario, Canada.
Abstract:
BackgroundSerosurveys for SARS-CoV-2 aim to estimate the proportion of the population that has been infected.AimThis observational study assesses the seroprevalence of SARS-CoV-2 antibodies in Ontario, Canada during the first pandemic wave.MethodsUsing an orthogonal approach, we tested 8,902 residual specimens from the Public Health Ontario laboratory over three time periods during March-June 2020 and stratified results by age group, sex and region. We adjusted for antibody test sensitivity/specificity and compared with reported PCR-confirmed COVID-19 cases.ResultsAdjusted seroprevalence was 0.5% (95% confidence interval (CI): 0.1-1.5) from 27 March-30 April, 1.5% (95% CI: 0.7-2.2) from 26-31 May, and 1.1% (95% CI: 0.8-1.3) from 5-30 June 2020. Adjusted estimates were highest in individuals aged ≥ 60 years in March-April (1.3%; 95% CI: 0.2-4.6), in those aged 20-59 years in May (2.1%; 95% CI: 0.8-3.4) and in those aged ≥ 60 years in June (1.6%; 95% CI: 1.1-2.1). Regional seroprevalence varied, and was highest for Toronto in March-April (0.9%; 95% CI: 0.1-3.1), for Toronto in May (3.2%; 95% CI: 1.0-5.3) and for Toronto (1.5%; 95% CI: 0.9-2.1) and Central East in June (1.5%; 95% CI: 1.0-2.0). We estimate that COVID-19 cases detected by PCR in Ontario underestimated SARS-CoV-2 infections by a factor of 4.9.ConclusionsOur results indicate low population seroprevalence in Ontario, suggesting that public health measures were effective at limiting the spread of SARS-CoV-2 during the first pandemic wave.
Insights
This study found low SARS-CoV-2 antibody prevalence in Ontario during the first pandemic wave, suggesting public health measures effectively limited virus spread. COVID-19 cases were underestimated by 4.9 times.
Area of Science:
- Epidemiology
- Immunology
- Public Health
Background:
- Serosurveys are crucial for estimating population infection rates of SARS-CoV-2.
- Understanding seroprevalence provides insights into the true extent of viral spread beyond reported cases.
Purpose of the Study:
- To assess the seroprevalence of SARS-CoV-2 antibodies in Ontario, Canada, during the initial phase of the pandemic.
- To analyze seroprevalence trends across different age groups, sexes, and regions during the first wave.
Main Methods:
- An observational study utilizing 8,902 residual specimens from the Public Health Ontario laboratory.
- Testing was conducted across three distinct time periods between March and June 2020.
- Results were adjusted for antibody test characteristics and compared with PCR-confirmed COVID-19 data.
Main Results:
- Adjusted seroprevalence ranged from 0.5% in late March-April to 1.5% in late May 2020.
- Higher seroprevalence was observed in older adults (≥60 years) during March-April and June, and in the 20-59 age group in May.
- Toronto consistently showed the highest regional seroprevalence across the study periods.
Conclusions:
- The study indicates a low overall population seroprevalence of SARS-CoV-2 in Ontario during the first pandemic wave.
- The findings suggest that implemented public health interventions were successful in controlling widespread transmission.
- PCR-detected COVID-19 cases likely underestimated total SARS-CoV-2 infections by a factor of approximately 4.9.
Related Concept Videos
Steps in Outbreak Investigation
Principles of Disease Surveillance
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Single Nucleotide Polymorphisms-SNPs

